Accepted Article

DR ELISABETTA DI LEO (Orcid ID : 0000-0002-9916-8211) PROFESSOR LUCA STINGENI (Orcid ID : 0000-0001-7919-8141) PROFESSOR FRANCO RONGIOLETTI (Orcid ID : 0000-0002-2227-581X) DR SIMONA TAVECCHIO (Orcid ID : 0000-0003-3546-4932) DR MADDALENA NAPOLITANO (Orcid ID : 0000-0003-3309-8190) DR SIMONE RIBERO (Orcid ID : 0000-0002-0098-1406) DR LAURA BONZANO (Orcid ID : 0000-0002-8933-4626) DR GIULIA CALABRESE (Orcid ID : 0000-0002-2013-4802) DR PAOLO ROMITA (Orcid ID : 0000-0002-5559-9722) DR AIKATERINI DETORAKI (Orcid ID : 0000-0002-3692-1384)

Article type

: Research Letter

Long-term effectiveness of dupilumab up to 52 weeks in atopic dermatitis in 253 adult patients E. Nettis,1 G. Fabbrocini,2 M. Ortoncelli,3 G. Pellacani,4 G. Argenziano,5 E. Di Leo,6 C. Patruno,7 L. Stingeni,8 C. Foti,9 F. Rongioletti,10 L. Macchia,1 S. Tavecchio,11 M. Napolitano,12 S. Ribero,3 L. Bonzano,13 G. Calabrese,5 D. Di Bona,1 S.P. Nisticò,7 K. Hansel,8 P. Romita,9 V. Piras,10 M. Carbonara,14 A. Detoraki15 and S.M. Ferrucci11

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/bjd.19577 This article is protected by copyright. All rights reserved

Accepted Article

1Department

of Emergency and Organ Transplantation, School and Chair of Allergology and

Clinical Immunology, University of Bari - Aldo Moro, Bari, Italy. 2Section

of Dermatology, Department of Clinical Medicine and Surgery, University of Naples

Federico II, Naples, Italy. 3Medical

Sciences Department, Dermatologic Clinic, University of Turin, Turin, Italy.

4Dermatology, 5Dermatology 6Section

University of Modena and Reggio Emilia, Modena, Italy. Unit, University of Campania, Naples, Italy.

of Allergy and Clinical Immunology, Unit of Internal Medicine-"F. Miulli" Hospital,

Acquaviva delle Fonti, Bari, Italy. 7Unit

of Dermatology, Department of Health Sciences, University Magna Graecia of Catanzaro,

Catanzaro, Italy. 8Dermatology 9Department

Section, Department of Medicine, University of Perugia, Perugia, Italy.

of Biomedical Science and Human Oncology, Unit of Dermatology, University of

Bari, Bari, Italy 10Unit

of Dermatology, Department of Medical Sciences and Public Health, University of Cagliari,

Italy.

11UOC

Dermatologia, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan,

Italy. Dipartimento di Fisiopatologia Medico‐Chirurgica e dei Trapianti, Università degli Studi di Milano, Milan, Italy. 12Department

of Medicine and Health Sciences “Vincenzo Tiberio”, University of Molise,

Campobasso, Italy. 13Allergology 14National

Service, AUSL Modena, Italy.

Institute of Statistics (ISTAT), Bari, Italy

15Department

of Internal Medicine and Clinical Pathology, Azienda Ospedaliera Universitaria

Federico II, Naples, Italy Corresponding author: Elisabetta Di Leo, MD, PhD E-mail: [email protected] ORCID: https://orcid.org/0000-0002-9916-8211.

IRB approval status: Reviewed and approved by the Ethics Committee of Naples Federico II University Hospital, Italy.

This article is protected by copyright. All rights reserved

Accepted Article

Funding sources: none Conflicts of Interest: The authors declare that they have no conflicts of interest except for - Luca Stingeni: consultant and speaker for Sanofi, Abbvie, Celgene, Novartis, Eli Lilly; - Katharina Hansel: consultant and speaker for Abbie, Celgene, Novartis; - Silvia Mariel Ferrucci is speaker of Novartis and Sanofi Genzyme; she is Principal Investigator for Eli Lilly, Abbvie, Sanofi Genzyme; she is an advisory board member of Sanofi Genzyme;

- Luigi Macchia: in the past five years accepted a fee for organizing education; - Caterina Foti: speaker for Sanofi, Abbvie; - Cataldo Patruno: speaker and consultant for AbbVie, Novartis, Pfizer, Sanofi Genzyme; - Franco Rongioletti consultant and Speaker for Abbvie, Sanofi, Janssen, Novartis, Almirall, Lilly; - Eustachio Nettis: in the past five years accepted a fee for organising education. Dear Editor, Dupilumab, an inhibitor of interleukin (IL)-4/13 activity, is a biological agent approved for

the treatment of moderate-to-severe atopic dermatitis (AD)1. Our aim was to assess the long-term

effectiveness and safety of dupilumab in a clinical real-life setting. A multicenter, retrospective study evaluated 253 adults (146 males; age 39.0±26.0 years) with severe AD. All patients fulfilled the criteria for dupilumab treatment of the Italian Drug Agency: age

≥18

years,

Eczema

Area

Severity

Index

(EASI)

score

≥24,

and

unresponsiveness/intolerance/contraindication to cyclosporine. Sixty-nine patients (27.3%) had adult-onset (≥18 years of age) and 184 (72.7%) early-onset (